Download Linnk AI
•
Autonomous Research Assistant
>
Sign In
insight
-
Zerlasiran siRNA Phase 2 Results
Zerlasiran siRNA Drug Reduces Lp(a) by 90% in Phase 2 Study
Zerlasiran siRNA significantly reduces Lp(a) levels by 90% in high-risk patients.
1